Benefiting from Taiwan’s major breakthroughs in the cell therapy market this year, including the Ministry of Health and Welfare’s conditional opening in March to allow exosomes from human cells to be used as cosmetic raw materials, and the dual regenerative medicine laws passed in the third reading of the Legislative Yuan in June, Taiwan’s medical The trillion yuan industry has officially started. Hexun’s demand for cell therapy process development and exosome production entrusted by customers has also increased significantly. Revenue in the first half of the year reached 133 million yuan, an annual increase of 384%, and disbursement exceeded 131 million yuan for the whole year of 2023. Excellent performance in revenue.
General Inferential Statistics, a foreign research institution, estimates that the global cell therapy CDMO market will reach US$12 billion in 2023. Urban development and the rise of the middle class in the Asia-Pacific region have led to an increase in overall demand for cell therapy, coupled with a strong manufacturing base. Cost-effective production, as well as supportive government policies, etc., provide Hexun and related supply chains with good room for business growth.
For the full text, please see the link below https://tw.news.yahoo.com/%E5%8F%97%E6%83%A0%E5%86%8D%E7%94%9F%E9%9B%99%E6% B3%95%E9%80%9A%E9%81%8E-%E5%92%8C%E8%BF%85%E5%A4%96%E6%B3%8C%E9%AB%94%E6%8E %A5%E5%96%AE%E8%BD%89%E7%86%B1-233727410.html